11 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
26985319	36	Potent and Selective CK2 Kinase Inhibitors with Effects on Wnt Pathway Signaling in Vivo.	Astrazeneca
26762835	342	Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).	Icahn School of Medicine At Mount Sinai
24650640	43	Discovery of 4-anilinoa-carbolines as novel Brk inhibitors.	Martin-Luther-University Halle-Wittenberg
24900749	6	Structure and Property Based Design of Pyrazolo[1,5-a]pyrimidine Inhibitors of CK2 Kinase with Activity in Vivo.	Astrazeneca
23394126	170	Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR).	Exelixis
24900464	66	Potent and Selective Inhibitors of CK2 Kinase Identified through Structure-Guided Hybridization.	TBA
17935989	146	Macrocyclic ureas as potent and selective Chk1 inhibitors: an improved synthesis, kinome profiling, structure-activity relationships, and preliminary pharmacokinetics.	Abbott Laboratories
22037378	31824	Comprehensive analysis of kinase inhibitor selectivity.	Ambit Biosciences
19654408	2521	AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).	Ambit Biosciences
18799313	20	Identification of novel protein kinase CK1 delta (CK1delta) inhibitors through structure-based virtual screening.	Università